{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:50:36Z","timestamp":1793213436961,"version":"4.5.0"},"reference-count":69,"publisher":"Informa UK Limited","issue":"9","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Clinical Pharmacology"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1080\/17512433.2016.1206467","type":"journal-article","created":{"date-parts":[[2016,6,27]],"date-time":"2016-06-27T11:33:33Z","timestamp":1467027213000},"page":"1145-1152","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":43,"title":["Tavaborole \u2013 a treatment for onychomycosis of the toenails"],"prefix":"10.1080","volume":"9","author":[{"given":"Aditya K.","family":"Gupta","sequence":"first","affiliation":[{"name":",","place":["Canada"]},{"name":"Mediprobe Research Inc., London, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah G.","family":"Versteeg","sequence":"additional","affiliation":[{"name":"Mediprobe Research Inc., London, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2016,7,14]]},"reference":[{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12168"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.7547\/0003-0538-104.4.330"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2012.01551.x"},{"key":"e_1_3_2_8_1","first-page":"s96","article-title":"Onchomycosis: an overview","volume":"12","author":"Elewski BE","year":"2013","unstructured":"Elewski BE, Rich P, Tosti A, et al. Onchomycosis: an overview. J Drugs Dermatol JDD. 2013;12:s96\u2013103.","journal-title":"J Drugs Dermatol JDD"},{"key":"e_1_3_2_9_1","first-page":"366","article-title":"The impact of nail disorders on quality of life","volume":"5","author":"Belyayeva E","year":"2013","unstructured":"Belyayeva E, Gregoriou S, Chalikias J, et al. The impact of nail disorders on quality of life. Eur J Dermatol. 2013;5-6:366\u2013371.","journal-title":"Eur J Dermatol"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/1751-0759-8-15"},{"key":"e_1_3_2_11_1","first-page":"1263","article-title":"Onychomycosis: burden of disease and the role of topical antifungal treatment","volume":"12","author":"Daniel RC","year":"2013","unstructured":"Daniel RC. Onychomycosis: burden of disease and the role of topical antifungal treatment. J Drugs Dermatol JDD. 2013;12:1263\u20131266.","journal-title":"J Drugs Dermatol JDD"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2003.05242.x"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12323"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12287"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.12788\/j.sder.0014"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.7547\/87507315-91-9-456"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1159\/000017990"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2005.01284.x"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1159\/000357764"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2013.06.011"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2012.681779"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2009.01107.x"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0152-x"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1159\/000247612"},{"key":"e_1_3_2_25_1","first-page":"10","article-title":"The role of topical antifungal therapy for onychomycosis and the emergence of newer agents","volume":"7","author":"Del Rosso JQ","year":"2014","unstructured":"Del Rosso JQ. The role of topical antifungal therapy for onychomycosis and the emergence of newer agents. J Clin Aesthetic Dermatol. 2014;7:10\u201318.","journal-title":"J Clin Aesthetic Dermatol"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.109071"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.109068"},{"key":"e_1_3_2_28_1","unstructured":"MHRA. Curanail 5% nail lacquer (amorolfine hydrochloride) PL 10590\/0049 [Internet]. [cited 2016 Mar 8]. Available from: http:\/\/www.mhra.gov.uk\/home\/groups\/l-unit1\/documents\/websiteresources\/con2023787.pdf."},{"key":"e_1_3_2_29_1","unstructured":"Valeant. Product monograph Penlac (ciclopirox topical solution 8% w\/w) nail lacquer [Internet]. 2012 [cited 2016 Mar 8]. Available from: http:\/\/webprod3.hc-sc.gc.ca\/dpd-bdpp\/info.do?lang=eng&code=73535."},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.10.013"},{"key":"e_1_3_2_31_1","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02063-12","article-title":"Mechanism of action of efinaconazole, a novel triazole antifungal agent","author":"Tatsumi Y","year":"2013","unstructured":"Tatsumi Y, Nagashima M, Shibanushi T, et al. Mechanism of action of efinaconazole, a novel triazole antifungal agent. Antimicrob Agents Chemother. 2013;57(5):2405\u20132409.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm0603724"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5173(01)00989-9"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425240802497218"},{"key":"e_1_3_2_35_1","first-page":"675","article-title":"In vitro nail penetration of tavaborole topical solution, 5%, through nail polish on ex vivo human fingernails","volume":"14","author":"Vlahovic T","year":"2015","unstructured":"Vlahovic T, MPharm TM, Chanda S, et al. In vitro nail penetration of tavaborole topical solution, 5%, through nail polish on ex vivo human fingernails. J Drugs Dermatol JDD. 2015;14:675\u2013678.","journal-title":"J Drugs Dermatol JDD"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2014.915738"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S81944"},{"key":"e_1_3_2_38_1","first-page":"609","article-title":"In vitro nail penetration and antifungal activity of tavaborole, a boron-based pharmaceutical","volume":"14","author":"Coronado D","year":"2015","unstructured":"Coronado D, Merchant T, Chanda S, et al. In vitro nail penetration and antifungal activity of tavaborole, a boron-based pharmaceutical. J Drugs Dermatol JDD. 2015;14:609\u2013614.","journal-title":"J Drugs Dermatol JDD"},{"key":"e_1_3_2_39_1","unstructured":"Mao W Rock FL Alley MR. AN2690 a topical antifungal agent in development for the treatment of onychomycosis represents a new class and has a novel mechanism of action [Internet]. 2006 [cited 2016 Mar 8]. Available from: http:\/\/www.anacor.com\/pdf\/SID_P769.pdf."},{"key":"e_1_3_2_40_1","unstructured":"Anacor Pharmaceuticals Inc. FDA approves Anacor Pharmaceuticals\u2019 KERYDINTM (tavaborole) topical solution 5% for the treatment of onychomycosis of the toenails [Internet]. 2014 [cited 2014 Nov 24]. Available from: http:\/\/investor.anacor.com\/releasedetail.cfm?ReleaseID=858211."},{"key":"e_1_3_2_41_1","unstructured":"Beutner KR Sanders V Hold K et al. An open-label multi-dose study of the absorption and systemic pharmacokinetics of AN2690 applied as a 7.5% solution to all toenails of adult patients with moderate to severe onychomycosis [Internet]. 2007 [cited 2013 Oct 21]. Available from: http:\/\/anacor.com\/pdf\/poster_1823.pdf."},{"key":"e_1_3_2_42_1","doi-asserted-by":"crossref","first-page":"AB124","DOI":"10.1016\/j.jaad.2006.10.582","article-title":"Interim results of a multi-center study to evaluate the safety and efficacy of topically applied AN2690 5.0% and 7.5% solution for the treatment of onychomycosis of the great toenail","volume":"56","author":"Beutner KR","year":"2007","unstructured":"Beutner KR, Toledo-Bahena M, Mata-Lara M, et al. Interim results of a multi-center study to evaluate the safety and efficacy of topically applied AN2690 5.0% and 7.5% solution for the treatment of onychomycosis of the great toenail. J Am Acad Dermatol. 2007;56:AB124.","journal-title":"J Am Acad Dermatol"},{"key":"e_1_3_2_43_1","first-page":"1124","article-title":"The efficacy and safety of tavaborole, a novel, boron-based pharmaceutical agent: phase 2 studies conducted for the topical treatment of toenail onychomycosis","volume":"13","author":"Toledo-Bahena ME","year":"2014","unstructured":"Toledo-Bahena ME, Bucko A, Ocampo-Candiani J, et al. The efficacy and safety of tavaborole, a novel, boron-based pharmaceutical agent: phase 2 studies conducted for the topical treatment of toenail onychomycosis. J Drugs Dermatol JDD. 2014;13:1124\u20131132.","journal-title":"J Drugs Dermatol JDD"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.04.010"},{"key":"e_1_3_2_45_1","first-page":"89","article-title":"Evaluation of the appearance of nail polish following daily treatment of ex vivo human fingernails with topical solutions of tavaborole or efinaconazole","volume":"15","author":"Coronado D","year":"2016","unstructured":"Coronado D, Vlahovic TC, Chanda S, et al. Evaluation of the appearance of nail polish following daily treatment of ex vivo human fingernails with topical solutions of tavaborole or efinaconazole. J Drugs Dermatol JDD. 2016;15:89\u201394.","journal-title":"J Drugs Dermatol JDD"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1177\/1091581814545245"},{"key":"e_1_3_2_47_1","article-title":"Tavaborole, a novel boron-containing small molecule pharmaceutical agent for topical treatment of onychomycosis: I. reproductive and developmental toxicity studies","author":"Ciaravino V","year":"2016","unstructured":"Ciaravino V, Coronado D, Lanphear C, et al. Tavaborole, a novel boron-containing small molecule pharmaceutical agent for topical treatment of onychomycosis: I. reproductive and developmental toxicity studies. Int J Toxicol. 2016:1\u201313. [Epub ahead of print]","journal-title":"Int J Toxicol"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(09)80305-8"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2011.11.001"},{"key":"e_1_3_2_50_1","unstructured":"Anacor Pharmaceuticals Inc. Kerydin (tavaborole) topical solution 5% [Internet]. 2014 [cited 2016 Mar 8]. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/204427s000lbl.pdf."},{"key":"e_1_3_2_51_1","unstructured":"Hold KM Bu W Sanders V et al. In vivo nail residence time of AN2690 a novel broad-spectrum antifungal agent in development for the topical treatment of onychomycosis [Internet]. 2007 [cited 2013 Oct 28]. Available from: http:\/\/anacor.com\/pdf\/poster_1816.pdf."},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2015.1034081"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2006.01230.x"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2004.00851.x"},{"key":"e_1_3_2_55_1","first-page":"702","article-title":"Diagnosis and management of tinea infections","volume":"90","author":"Ely JW","year":"2014","unstructured":"Ely JW, Rosenfeld S, Stone MS. Diagnosis and management of tinea infections. Am Fam Physician. 2014;90:702\u2013710.","journal-title":"Am Fam Physician"},{"key":"e_1_3_2_56_1","first-page":"223","article-title":"Onychomycosis: epidemiology, diagnosis, and treatment in a changing landscape","volume":"14","author":"Rosen T","year":"2015","unstructured":"Rosen T, Friedlander SF, Kircik L, et al. Onychomycosis: epidemiology, diagnosis, and treatment in a changing landscape. J Drugs Dermatol JDD. 2015;14:223\u2013233.","journal-title":"J Drugs Dermatol JDD"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.02464.x"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200421020-00003"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10227-003-0109-x"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.12064"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(98)70481-5"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.104794"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.149.s65.5.x"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1159\/000073086"},{"key":"e_1_3_2_65_1","first-page":"10","article-title":"Onychomycosis: review of recurrence rates, poor prognostic factors, and strategies to prevent disease recurrence","volume":"74","author":"Gupta AK","year":"2004","unstructured":"Gupta AK, Lynch LE. Onychomycosis: review of recurrence rates, poor prognostic factors, and strategies to prevent disease recurrence. Cutis. 2004;74:10\u201315.","journal-title":"Cutis"},{"key":"e_1_3_2_66_1","first-page":"279","article-title":"Onychomycosis: strategies to minimize recurrence","volume":"15","author":"Gupta AK","year":"2016","unstructured":"Gupta AK, Elewski BE, Rosen T, et al. Onychomycosis: strategies to minimize recurrence. J Drugs Dermatol JDD. 2016;15:279\u2013282.","journal-title":"J Drugs Dermatol JDD"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20901"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.16.2.157"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1994.01690050022003"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.01.893"},{"key":"e_1_3_2_71_1","unstructured":"US Food and Drug Administration. Medical devices and clinical trial design for the treatment or improvement in the appearance of fungally-infected nails \u2013 draft guidance for industry and FDA staff [Internet]. 2015 [cited 2015 May 22]. Available from: http:\/\/www.fda.gov\/downloads\/MedicalDevices\/DeviceRegulationandGuidance\/GuidanceDocuments\/UCM431312.pdf."},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm050676a"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi5000564"}],"container-title":["Expert Review of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17512433.2016.1206467","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T13:37:57Z","timestamp":1770385077000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17512433.2016.1206467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,14]]},"references-count":69,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["10.1080\/17512433.2016.1206467"],"URL":"https:\/\/doi.org\/10.1080\/17512433.2016.1206467","relation":{},"ISSN":["1751-2433","1751-2441"],"issn-type":[{"value":"1751-2433","type":"print"},{"value":"1751-2441","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,14]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2016-05-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-06-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-07-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}